Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547912 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL29397967 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL29401862 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL3725027 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL3725031 | 1.00 | MDM4 (0.53) | MDM4TP53SLC17A5CASP3HRH4 | |
| SCHEMBL13978398 | 0.91 | MDM4 (0.47) | MDM4TP53SLC17A5CASP3CTSS | |
| SCHEMBL24915806 | 0.89 | MDM4 (0.50) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL30229636 | 0.89 | MDM4 (0.50) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL29221380 | 0.89 | MDM4 (0.50) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL30229510 | 0.89 | MDM4 (0.50) | MDM4TP53SLC17A5CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025007839-A1 | CONJUGATE COMPOUND, AND PREPARATION METHOD THEREOF AND USE THEREOF | 韦恩生物科技有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-20240173422-A1 | BICYCLIC PEPTIDE LIGAND DRUG CONJUGATES | BICYCLETX LIMITED (GB) | 2024-05-30 | — | — | US | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-117377759-A | Self-purified nucleic acid-encoded libraries | 约尔格·谢尔曼 | 2024-01-09 | — | — | CN | disclosed |
| US-6037323-A | PEPTIDES AND PEPTIDE ANALOGUES THAT MIMIC THE STRUCTURAL AND PHARMACOLOGICAL PROPERTIES OF HUMAN APOA-I; TREATING DISORDERS ASSOCIATED WITH DYSLIPOPROTEINEMIA, INCLUDING HYPERCHOLESTEROLEMIA, CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS, | Dasseux, Jean-Louis (DE) | 2000-03-14 | — | — | US | disclosed |
| US-6004925-A | POLYPEPTIDE ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS, RESTENOSIS, ATHEROSCLEROSIS | Dasseux, J. L. (FR) | 1999-12-21 | — | — | US | disclosed |
| EP-0384362-B1 | Glycinderivatives | HOFFMANN LA ROCHE (CH) | 1999-12-15 | — | — | EP | disclosed |
| WO-1999016459-A1 | APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS | DASSEUX JEAN LOUIS (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999016458-A1 | APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS | DASSEUX JEAN LOUIS (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999016408-A2 | APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS | DASSEUX JEAN LOUIS (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998052890-A1 | 3-ARYLPROPYLAMINO NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-11-26 | — | — | WO | disclosed |
| US-5663297-A | OLIGOPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-4548926-A | RENIN INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0128762-A2 | New hypotensive peptides, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885SLC17A5 569/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MDM4 1648/4885TP53 614/4885SLC17A5 984/4885 |
| US-20240173422-A1 | BICYCLIC PEPTIDE LIGAND DRUG CONJUGATES | BID, BAD, MCL1 | MDM4 2272/4885TP53 49/4885SLC17A5 1277/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885SLC17A5 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.